Veana Therapeutics
Andrew Ray, Ph.D., is the co-founder of KromaTID, Inc., a privately-held company that developed Directional Genomic Hybridization (dGH™) platform technology capable of detecting DNA sequence, location, and orientation in a single test. He has co-authored over 40 publications and holds 7 US and European patents for his work.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Veana Therapeutics
Veana Therapeutics is dedicated to developing innovative, safe, cancer-fighting immunotherapeutic products.